Evaluation of Serum Tumor Endothelial Marker1 as a Potential Biomarker for Colorectal Cancer Diagnosis and Cancer Progression
1 other identifier
observational
90
0 countries
N/A
Brief Summary
Aim of work
- 1.measurement level of serumTEM1 in CRC patients by ng/ml using ELISA kits .
- 2.find relation between serum TEM1 level and staging of CRC patients .
- 3.measurement of serum CEA , CA19-9 levels by ng/ml so we can can compare their levels with serum TEM1 level in CRC patients .
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2023
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 14, 2023
CompletedFirst Posted
Study publicly available on registry
March 22, 2023
CompletedStudy Start
First participant enrolled
May 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
ExpectedMarch 22, 2023
March 1, 2023
2.8 years
January 14, 2023
March 20, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Tumor endothelial marker 1 in colorectal cancer
1. measurement level of serumTEM1 in CRC patients by ng/ml using ELISA kits . 2. measurement of serum CEA , CA19-9 levels by ng/ml
baseline
Study Arms (2)
Group (1)(patient group):
who are 50 newly diagnosed patient with colorectal cancer, who will be admitted at South Egypt Cancer Inistitute and Assiut University Hospital during 2023. Patients group will be furtherly subclassified according to the American Joint Committee on Cancer Staging,TNM staging classification
Group (2) (control group)
40 apparently healthy individuals with matched age and sex are included in this study as a control group for comparison.
Interventions
measurement of serum TEM1 in CRC patients, its relation to staging and comparing the diagnostic performance of serum TEM1 with serum CEA and CA19-9 for diagnosis of CRC. and Early detection of CRC patient
Eligibility Criteria
* Fifty patients who were diagnosed by (lower endoscopy, multislice CT abdomen or histopathology analysis of the lesion), tumor staging was classified according to the American Joint Committee on Cancer Staging,TNM staging classification. * Patients did not receive any chemotherapy or undergo surgical treatment * Forty apparently healthy individuals with matched age and sex are included in this study as a control group for comparison
You may qualify if:
- newly diagnosed CRC patients.
You may not qualify if:
- chemotherapy
- radiotherapy
- surgical treatment
- heart failure
- angina
- liver cirrhosis
- renal cell carcinoma
- gastric cancer.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assiut lecturer
Study Record Dates
First Submitted
January 14, 2023
First Posted
March 22, 2023
Study Start
May 1, 2023
Primary Completion
February 1, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
March 22, 2023
Record last verified: 2023-03